{"id":"NCT01041573","sponsor":"Valneva Austria GmbH","briefTitle":"Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population","officialTitle":"Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population. Open Label, Randomized, Active Controlled, Phase 3 Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-03","primaryCompletion":"2011-02","completion":"2011-07","firstPosted":"2009-12-31","resultsPosted":"2014-02-27","lastUpdate":"2021-07-27"},"enrollment":1869,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Encephalitis"],"interventions":[{"type":"BIOLOGICAL","name":"IC51 Japanese Encephalitis","otherNames":[]},{"type":"BIOLOGICAL","name":"Havrix®720","otherNames":[]},{"type":"BIOLOGICAL","name":"Prevnar","otherNames":[]}],"arms":[{"label":"IC51 0.5 mL","type":"EXPERIMENTAL"},{"label":"IC51 0.25 mL","type":"EXPERIMENTAL"},{"label":"Havrix 720","type":"ACTIVE_COMPARATOR"},{"label":"Prevnar","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective is to assess the systemic and local safety profile of purified inactivated Japanese Encephalitis Virus (JEV) vaccine IC51 administered in two doses in a 28 days interval up to Month 7 after the first IC51 vaccination in a pediatric population from endemic regions.","primaryOutcome":{"measure":"Rate of Subjects With Serious Adverse Events and Medically Attended Adverse Events Until Day 56 After First Vaccination","timeFrame":"until Day 56","effectByArm":[{"arm":"IC51, Subjects Aged >= 1 Year","deltaMin":16.1,"sd":null},{"arm":"Havrix 720","deltaMin":14.2,"sd":null},{"arm":"IC51, Subjects Aged >= 2 Months to <1 Year","deltaMin":38.2,"sd":null},{"arm":"Prevnar","deltaMin":42.2,"sd":null}],"pValues":[{"comp":"OG002 vs OG003","p":"0.641"},{"comp":"OG000 vs OG001","p":"< 0.001"}]},"eligibility":{"minAge":"2 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":2,"countries":["Philippines"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":871},"commonTop":["Upper Respiratory Tract Infection","Fever","Pyrexia","Redness","Nasopharyngitis"]}}